Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Development of the Oncology Opportunity Cost Assessment Tool

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04694911
Recruitment Status : Recruiting
First Posted : January 5, 2021
Last Update Posted : January 5, 2021
Sponsor:
Information provided by (Responsible Party):
Thomas Jefferson University

Brief Summary:
This study develops and tests an instrument to measure opportunity costs called the Oncology Opportunity Cost Assessment Tool (OOCAT) in cancer patients. Patients experience significant costs, both direct financial as well as indirect costs, associated with seeking cancer treatment. While the direct financial impact of care on patients is receiving increased attention, other important consequences, such as opportunity cost, remain largely unmeasured. Opportunity cost is an economics term that refers to the loss of potential benefits from other options when one option is chosen - if resources are used for one purpose, they are no longer available for the next best option. The information and knowledge gained from this study may help researchers develop the OOCAT, which may allow them to understand the opportunity cost of treatment for each patient. The OOCAT may then be used to determine not just the best medications for patients, but also the best comprehensive treatment plan that will allow them to get the right treatment in the right place at the right time.

Condition or disease Intervention/treatment
Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm Behavioral: Focus Group Other: Interview Other: Research or Clinical Assessment Tool

Layout table for study information
Study Type : Observational
Estimated Enrollment : 172 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Development of the Oncology Opportunity Cost Assessment Tool (OOCAT)
Actual Study Start Date : November 21, 2019
Estimated Primary Completion Date : January 2021
Estimated Study Completion Date : January 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Health Checkup

Group/Cohort Intervention/treatment
Health Services Research (focus group, interview, OOCAT)

FOCUS GROUP: Patients participate in focus group session over 60-90 minutes.

COGNITIVE INTERVIEW: Patients complete cognitive interview on the clarity, interpretability, and ease of use of the OOCAT.

FEASIBILITY TESTING: Patients receive OOCAT at the point of care, online, or via telephone, per patients' preference.

Behavioral: Focus Group
Participate in focus group

Other: Interview
Complete cognitive interview

Other: Research or Clinical Assessment Tool
Receive OOCAT
Other Name: Clinical Assessment Tool, Clinical Assessment Tool, Clinical or Research Assessment Tool




Primary Outcome Measures :
  1. Patient-level opportunity costs associated with oncology care [ Time Frame: 1 Day of Interview ]
    Patient-identified themes that contribute to opportunity cost will be generated via patient focus groups

  2. Development of the Oncology Opportunity Cost Assessment Tool (OOCAT) [ Time Frame: 1 Day of Interview ]
    Will organize themes into domains and will generate items representing each of the themes for inclusion in an instrument designed to measure patient opportunity cost of seeking care. Will perform cognitive interviews with a random sampling of patients from the cancer center to test initial instrument items to ensure content validity and clarity of each item.

  3. Implementation of OOCAT [ Time Frame: 1 Day of OOCAT administration ]
    Will test the instrument as developed with patients receiving oncology care across the Jefferson Health System to gather preliminary data informing the reliability of the scale to measure opportunity cost of seeking care.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Sampling Method:   Non-Probability Sample
Study Population
Patients treated for cancer at Jefferson Center City, Jefferson Methodist Hospital, or Jefferson Abington
Criteria

Inclusion Criteria:

  • Treated for cancer at one of the 3 participating sites (Jefferson Center City, Jefferson Methodist Hospital, Jefferson Abington)
  • English speaking
  • Able to attend and participate in a focus group

Exclusion Criteria:

  • Treated at a Jefferson site other than the ones mentioned
  • Non-English Speaking

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04694911


Contacts
Layout table for location contacts
Contact: Nathan Handley, MD 215-955-8874 Nathan.Handley@jefferson.edu

Locations
Layout table for location information
United States, Pennsylvania
Sidney Kimmel Cancer Center at Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Nathan Handley, MD    215-955-8874    Nathan.Handley@jefferson.edu   
Sponsors and Collaborators
Thomas Jefferson University
Layout table for additonal information
Responsible Party: Thomas Jefferson University
ClinicalTrials.gov Identifier: NCT04694911    
Other Study ID Numbers: 19G.854
First Posted: January 5, 2021    Key Record Dates
Last Update Posted: January 5, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms